Current Status of PRP Manufacturing Requirements and European Regulatory Frameworks: Practical Tools for the Appropriate Implementation of PRP Therapies in Musculoskeletal Regenerative Medicine
February 2023
in “
Bioengineering
”
TLDR Standardizing PRP therapy practices and regulations in Europe is crucial for safe and effective treatment.
The document examines the challenges and regulatory requirements for implementing platelet-rich plasma (PRP) therapies in musculoskeletal regenerative medicine across Europe, emphasizing the need for standardization and adherence to good manufacturing practices (GMP). It highlights the variability in regulations among countries like Switzerland, Germany, France, Italy, and Spain, and underscores the importance of understanding legal requirements and engaging with competent authorities. The document serves as a practical guide for clinicians, providing insights into the biological functions of PRP, such as promoting tissue healing and reducing inflammation, and offering recommendations for optimizing PRP quality through standardized manufacturing processes. It also discusses the roles of regulatory bodies like Swissmedic and the European Medicines Agency in ensuring the safety and efficacy of PRP treatments.
